Trod Medical is mentioned in Medical Device Daily
PARIS - There are often incremental changes to electrosurgical devices, but few true innovations, which may explain the enthusiasm at Trod Medical NV for announcing a new patent. Based in Leuven, Belgium, the company received a fresh layer of protection from the United States Patent and Trademark Office in February 2017 for the Encage bipolar helical ablation probe, a novel method percutaneous treatment of prostate lesions using radio frequency (RF).
The new patent, combined with a growing body of evidence that the Encage device can destroy prostate tumors without destroying a man's quality of life "puts Trod Medical in a dominant position in this very significant and growing market," according to Trod Medical CEO Andre Faure.
More info on TROD Medical's website.
Next > Avantium launches its initial public offering on Euronext Amsterdam and Euronext Brussels
Previous > Jungbunzlauer and Green Biologics Partner on Bio-Based Plasticizers